Evofem Revenue Jumps 16 Percent in Q2
Evofem Biosciences (OTC:EVFM), a specialty biopharmaceutical company focused on women’s sexual and reproductive health, reported financial results for Q2 2025 on August 14, 2025. The headline news was a 16.0% increase in GAAP net sales to $4.8 million in Q2 2025 compared to the prior-year quarter, driven by the addition of SOLOSEC and a price adjustment for PHEXXI. GAAP loss from operations improved modestly to $(1.3) million in Q2 2025 compared with the prior-year period, but GAAP net loss attributable to common stockholders reversed from income of $1.3 million to a loss of $(1.8) million in Q2 2025. There were no available analyst estimates for the quarter, so performance versus consensus cannot be assessed. Overall, the period showed operational progress but the results highlight ongoing losses (GAAP net loss attributable to common stockholders of $1.8 million in Q2 2025), weak liquidity (cash, cash equivalents, and restricted cash totaling $0.7 million as of June 30, 2025), and dependence on the upcoming merger with Aditxt for continued operations.
Evofem Biosciences targets the women’s health market with specialty products addressing sexual and reproductive conditions. It developed PHEXXI, a hormone-free prescription contraceptive vaginal gel, and more recently acquired SOLOSEC, an oral antibiotic for sexual health infections. Its commercial performance relies on the adoption of these products in the U.S. and future expansion into international markets.
The company has focused on increasing patient awareness, geographic expansion, and broadening product offerings. Key success factors include robust marketing for PHEXXI, regulatory progress for international entry, and cost controls to improve margins. Financial stability and access to external capital remain critical as Evofem scales its portfolio and prepares for its planned merger with Aditxt.
Source Fool.com
